Chemoimmunotherapy as long-term maintenance therapy for cancer

Homeostatic immune regulatory mechanisms can mediate premature termination of therapy-induced antitumor T-effector cell responses. Administration of cyclophosphamide (CY) prior to intratumoral IL-12 and GM-CSF delivery blocked post-treatment T-suppressor cell rebound via elimination of the pre-exist...

Descripción completa

Detalles Bibliográficos
Autores principales: Egilmez, Nejat K., Harden, Jamie L., Rowswell-Turner, Rachael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382905/
https://www.ncbi.nlm.nih.gov/pubmed/22754788
_version_ 1782236571857059840
author Egilmez, Nejat K.
Harden, Jamie L.
Rowswell-Turner, Rachael B.
author_facet Egilmez, Nejat K.
Harden, Jamie L.
Rowswell-Turner, Rachael B.
author_sort Egilmez, Nejat K.
collection PubMed
description Homeostatic immune regulatory mechanisms can mediate premature termination of therapy-induced antitumor T-effector cell responses. Administration of cyclophosphamide (CY) prior to intratumoral IL-12 and GM-CSF delivery blocked post-treatment T-suppressor cell rebound via elimination of the pre-existing T-suppressor cell pool, allowed repeated activation of antitumor cytotoxic T-cells and resulted in the cure of advanced spontaneous tumors.
format Online
Article
Text
id pubmed-3382905
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33829052012-07-01 Chemoimmunotherapy as long-term maintenance therapy for cancer Egilmez, Nejat K. Harden, Jamie L. Rowswell-Turner, Rachael B. Oncoimmunology Author's View Homeostatic immune regulatory mechanisms can mediate premature termination of therapy-induced antitumor T-effector cell responses. Administration of cyclophosphamide (CY) prior to intratumoral IL-12 and GM-CSF delivery blocked post-treatment T-suppressor cell rebound via elimination of the pre-existing T-suppressor cell pool, allowed repeated activation of antitumor cytotoxic T-cells and resulted in the cure of advanced spontaneous tumors. Landes Bioscience 2012-07-01 /pmc/articles/PMC3382905/ /pubmed/22754788 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Egilmez, Nejat K.
Harden, Jamie L.
Rowswell-Turner, Rachael B.
Chemoimmunotherapy as long-term maintenance therapy for cancer
title Chemoimmunotherapy as long-term maintenance therapy for cancer
title_full Chemoimmunotherapy as long-term maintenance therapy for cancer
title_fullStr Chemoimmunotherapy as long-term maintenance therapy for cancer
title_full_unstemmed Chemoimmunotherapy as long-term maintenance therapy for cancer
title_short Chemoimmunotherapy as long-term maintenance therapy for cancer
title_sort chemoimmunotherapy as long-term maintenance therapy for cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382905/
https://www.ncbi.nlm.nih.gov/pubmed/22754788
work_keys_str_mv AT egilmeznejatk chemoimmunotherapyaslongtermmaintenancetherapyforcancer
AT hardenjamiel chemoimmunotherapyaslongtermmaintenancetherapyforcancer
AT rowswellturnerrachaelb chemoimmunotherapyaslongtermmaintenancetherapyforcancer

Ejemplares similares